论文部分内容阅读
自1965年以来,虽开发了许多可以口服的头孢类制剂,但由于存在着抗菌效果增强则产生肠道吸收不好,而吸收良好的则抗菌效果又下降等缺点,因此有必要开发出抗菌力强,抗菌谱更广,对β-内酰胺酶稳定的口服头孢类药物。去年日本第35届化学疗法学会上,介绍了cefpodoxime proxetile、SCE-2174 2只可口服的头孢菌素新药。两药均具有抗菌谱广,抗菌活力强的特点,而且对革兰氏阴性菌中的流感菌、卡他布兰汉氏菌、大肠杆菌、
Since 1965, although many oral cephalosporins have been developed, there is a shortcoming that intestinal absorption is not good due to the enhanced antibacterial effect, while the absorption is good, the antibacterial effect is decreased. Therefore, it is necessary to develop an antibacterial force Strong, broad antibacterial spectrum, β-lactamase stable oral cephalosporins. Last year Japan 35th Chemotherapy Society, introduced cefpodoxime proxetile, SCE-2174 2 oral cephalosporins new drugs. Both drugs have broad antibacterial spectrum, strong antibacterial activity characteristics, but also Gram-negative bacteria in the flu, Crab dengue bacteria, Escherichia coli,